C Kruse1,2, P Eiken3,4, P Vestergaard5,6. 1. Department of Endocrinology, Aalborg University Hospital, Hobrovej 19, 9100, Aalborg, Denmark. ckruse@dcm.aau.dk. 2. Department of Clinical Medicine, Aalborg University Hospital, Aalborg, Denmark. ckruse@dcm.aau.dk. 3. Department of Cardiology, Nephrology and Endocrinology, Nordsjaellands Hospital, Hilleroed, Denmark. 4. Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 5. Department of Endocrinology, Aalborg University Hospital, Hobrovej 19, 9100, Aalborg, Denmark. 6. Department of Clinical Medicine, Aalborg University Hospital, Aalborg, Denmark.
Abstract
UNLABELLED: A study of national Danish patient data with regard to thiazide diuretics vs. non-treatment. We find that after age 83 years, thiazides increase the 10-year risk of major fractures. We also find that thiazides can be stopped after 63 years old to possibly protect against fracture occurrence. INTRODUCTION: The purpose of this study was to retrospectively examine the optimal age for commencing and discontinuing thiazide therapy to protect from osteoporotic fractures. METHODS: A population-based, retrospective matched cohort study was done using national data of 2.93 million Danish subjects. Ten-year crude and adjusted age-grouped hazard ratios (HRs) of fracture occurrence were stratified by age of commencing thiazides compared to non-exposure. Separate analyses were done on Anatomical Therapeutic Chemical Classification System (ATC) codes C03AA and C03AA + C03AB compiled. Ten-year crude HRs of fracture occurrence for discontinuing vs. continuing thiazides were estimated and stratified by age for the two groups. RESULTS: For C03AB alone (97.1 % of thiazide prescriptions), adjusted 10-year HRs of fracture occurrence were significantly increased for thiazide commencement after age 83 years and comparable to non-exposure for commencement between ages 50 and 83 years. For C03AA + C03AB, 10-year adjusted HRs of fracture occurrence were significantly increased from ages 73 years and upwards. Crude 10-year HRs of fracture occurrence were significantly decreased for discontinuing vs. continuing thiazides at or after age 63 years for C03AB and age 77 years for C03AA + C03AB. CONCLUSIONS: No significantly protective effect of thiazides was found on fracture occurrence compared to non-users, but evidence that thiazides increase the 10-year adjusted HR risk of fractures if prescribed after the age of 83 years for C03AB and 73 years for C03AA + C03AB. Discontinuing thiazides at or after age 63 years for C03AB or 77 years for C03AA & C03AB significantly decreases the 10-year risk of fractures compared to continuing thiazides. Further prospective studies are warranted.
UNLABELLED: A study of national Danish patient data with regard to thiazide diuretics vs. non-treatment. We find that after age 83 years, thiazides increase the 10-year risk of major fractures. We also find that thiazides can be stopped after 63 years old to possibly protect against fracture occurrence. INTRODUCTION: The purpose of this study was to retrospectively examine the optimal age for commencing and discontinuing thiazide therapy to protect from osteoporotic fractures. METHODS: A population-based, retrospective matched cohort study was done using national data of 2.93 million Danish subjects. Ten-year crude and adjusted age-grouped hazard ratios (HRs) of fracture occurrence were stratified by age of commencing thiazides compared to non-exposure. Separate analyses were done on Anatomical Therapeutic Chemical Classification System (ATC) codes C03AA and C03AA + C03AB compiled. Ten-year crude HRs of fracture occurrence for discontinuing vs. continuing thiazides were estimated and stratified by age for the two groups. RESULTS: For C03AB alone (97.1 % of thiazide prescriptions), adjusted 10-year HRs of fracture occurrence were significantly increased for thiazide commencement after age 83 years and comparable to non-exposure for commencement between ages 50 and 83 years. For C03AA + C03AB, 10-year adjusted HRs of fracture occurrence were significantly increased from ages 73 years and upwards. Crude 10-year HRs of fracture occurrence were significantly decreased for discontinuing vs. continuing thiazides at or after age 63 years for C03AB and age 77 years for C03AA + C03AB. CONCLUSIONS: No significantly protective effect of thiazides was found on fracture occurrence compared to non-users, but evidence that thiazides increase the 10-year adjusted HR risk of fractures if prescribed after the age of 83 years for C03AB and 73 years for C03AA + C03AB. Discontinuing thiazides at or after age 63 years for C03AB or 77 years for C03AA & C03AB significantly decreases the 10-year risk of fractures compared to continuing thiazides. Further prospective studies are warranted.
Entities:
Keywords:
Bone metabolism; Fractures; Osteoporosis; Post-menopausal; Thiazides
Authors: S Adami; D Gatti; F Bertoldo; M Rossini; A Fratta-Pasini; N Zamberlan; E Facci; V Lo Cascio Journal: Osteoporos Int Date: 1992-07 Impact factor: 4.507
Authors: Ewout J Hoorn; Fernando Rivadeneira; Joyce B J van Meurs; Gijsbertus Ziere; Bruno H Ch Stricker; Albert Hofman; Huibert A P Pols; Robert Zietse; André G Uitterlinden; M Carola Zillikens Journal: J Bone Miner Res Date: 2011-08 Impact factor: 6.741
Authors: Jennifer L Kelsey; Mila M Prill; Theresa H M Keegan; Heather E Tanner; Allan L Bernstein; Charles P Quesenberry; Stephen Sidney Journal: Osteoporos Int Date: 2004-10-26 Impact factor: 4.507
Authors: J A Cauley; S R Cummings; D G Seeley; D Black; W Browner; L H Kuller; M C Nevitt Journal: Ann Intern Med Date: 1993-05-01 Impact factor: 25.391
Authors: A D Dede; G Trovas; E Chronopoulos; I K Triantafyllopoulos; I Dontas; N Papaioannou; S Tournis Journal: Osteoporos Int Date: 2017-02-13 Impact factor: 4.507
Authors: D Canoy; N C Harvey; D Prieto-Alhambra; C Cooper; H E Meyer; B O Åsvold; M Nazarzadeh; K Rahimi Journal: Osteoporos Int Date: 2021-10-13 Impact factor: 5.071